Mitochondria-Loaded Vesicles Drive Immune Dysfunction in Asthma
Airway immune cells package mitochondria into tiny vesicles that hijack T cells, fueling the chronic inflammation defining asthma.
Summary
Researchers at UAB discovered that myeloid-derived regulatory cells (MDRCs) in asthmatic airways release small extracellular vesicles (sEVs) loaded with functional mitochondria. These vesicles engage T cell receptors and transfer mitochondria into CD4+ T cells, triggering NF-κB signaling via mitochondrial oxidants. This cascade drives aberrant T cell proliferation and polarization into pro-inflammatory Th2 and Th17 subsets. The mitochondrial fission protein DRP-1 regulates mitochondrial packaging into sEVs. In mice, intranasal delivery of mitochondria-packed sEVs worsened allergic airway inflammation, validating the in vivo relevance. Blocking oxidant-dependent NF-κB signaling suppressed T cell activation, pointing to a potentially actionable therapeutic target in asthma.
Detailed Summary
Asthma involves persistent airway inflammation driven by dysregulated CD4+ T helper cells, particularly Th2 and Th17 subsets, yet the mechanisms sustaining this immune dysfunction have remained incompletely understood. This study reveals a previously unrecognized signaling axis: mitochondria-containing small extracellular vesicles (sEVs) released by airway myeloid-derived regulatory cells (MDRCs) reprogram T helper cell identity and fuel chronic inflammation.
Using bronchoalveolar lavage fluid (BALF) from human asthmatics and healthy controls, the researchers characterized sEVs (predominantly 65–150 nm) and found that asthmatic-derived sEVs carry elevated HLA-DR, CD86, CD81, and CD54—molecules associated with antigen presentation and immune co-stimulation. Critically, these sEVs contained functional mitochondria with intact membrane potential, a feature linked to their immunostimulatory capacity.
When MDRC-derived sEVs from asthmatics were incubated with naïve CD4+ T cells, they induced antigen-specific T cell proliferation and polarization into Th17 and Th2 phenotypes. Mechanistically, sEV-transferred mitochondria generated reactive oxygen species (ROS) that activated NF-κB signaling within recipient T cells—a pathway central to inflammatory gene expression. Pharmacological blockade of mitochondrial oxidants or NF-κB significantly attenuated T cell activation. The mitochondrial fission GTPase DRP-1 was identified as the key regulator of mitochondrial packaging into sEVs; inhibiting DRP-1 reduced mitochondrial content in sEVs and blunted their T cell-activating capacity.
Internalized sEVs co-localized with the polarized cytoskeleton and mitochondrial networks in recipient T cells, suggesting that transferred mitochondria integrate into T cell bioenergetic infrastructure and reshape cellular metabolism to support the activated, polarized phenotype. In vivo validation using a murine allergic asthma model showed that intranasal transfer of mitochondria-enriched sEVs significantly enhanced Th2 and Th17 polarization and worsened allergic airway inflammation compared to mitochondria-depleted sEVs.
Collectively, these findings establish a novel immunological circuit in which DRP-1-dependent mitochondrial fission enables packaging of functional mitochondria into MDRC-sEVs, which then mediate acellular antigen presentation, mitochondrial ROS-driven NF-κB activation, and Th cell reprogramming—sustaining the chronic airway inflammation hallmark of asthma. The work positions DRP-1, sEV-mitochondrial transfer, and oxidant-NF-κB signaling as candidate therapeutic targets for disrupting this pathological loop.
Key Findings
- Asthmatic airway MDRC-derived sEVs carry functional mitochondria that activate CD4+ T cell proliferation and Th2/Th17 polarization.
- Mitochondrial ROS-driven NF-κB signaling in recipient T cells mediates sEV-induced immune activation; blocking it suppresses T cell responses.
- DRP-1 (mitochondrial fission GTPase) governs mitochondrial packaging into sEVs; DRP-1 inhibition reduces sEV immunostimulatory capacity.
- Internalized sEVs integrate with the recipient T cell cytoskeleton and mitochondrial network, reshaping cellular architecture.
- Intranasal transfer of mitochondria-loaded sEVs worsens allergic airway inflammation and Th polarization in a murine asthma model.
Methodology
Human BALF sEVs were isolated from asthmatics and healthy controls, characterized by nanoparticle tracking, flow cytometry, and electron microscopy, then co-cultured with naïve CD4+ T cells to assess proliferation and cytokine polarization. Mechanistic studies used pharmacological inhibitors of DRP-1, mitochondrial ROS, and NF-κB. In vivo validation employed intranasal sEV transfer in a murine allergic asthma model.
Study Limitations
The study relies primarily on ex vivo human BALF samples with inherent variability in disease severity and treatment history, and the murine model may not fully recapitulate human asthma heterogeneity. Causal directionality of sEV-mitochondrial transfer in longitudinal human disease progression remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: